Observational Study to Examine the Procedural and Outcomes of AF Ablation Assisted by STAR Apollo™ Mapping System
Eligible age
18–80 yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
STAR Apollo Mapping System is an FDA cleared mapping technology that can analyze the signals collected during the ablation procedure on the 3D mapping system and give the physician further insight into the AF activation patterns which may assist them in identifying areas responsible for maintaining Atrial Fibrillation (AF). The STAR Apollo Mapping System system allows clinicians, after treating the Pulmonary Veins (PV), to collect data from the atria during clinical AF procedures using standard FDA cleared catheters and devices. This study aims to examine the impact of the STAR Apollo Mapping System on procedural and acute outcomes in a multicenter observational study.
Sponsor: Kansas City Heart Rhythm Research Foundation
You may qualify if…
- ✓ Indication for ablation of persistent AF
- ✓ Age \>18 years
- ✓ Persistent AF \>7 days and total continuous duration \<2 years
- ✓ Patients have previously undergone pulmonary vein isolation, using any technique and have had AF recurrence.
- ✓ Patients have limited additional ablation at their first procedure (e.g. right atrial flutter line).
You may not qualify if…
- ✕ Patients with previous ablation in more than one region of the left atrium in addition to the pulmonary veins.
- ✕ Patients with longstanding persistent AF (continuous duration \>2 years) or significant substrate (mitral valve disease, scarring, very dilated atria \>50mm).
- ✕ Creatinine clearance estimated glomerular filtration rate (eGFR) \<30mls/min
- ✕ Contraindication to anticoagulation
Where it's recruiting
Source: ClinicalTrials.gov · NCT05826665 · last updated 2024-10-16